Navigation Links
Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
Date:11/2/2010

BASKING RIDGE, N.J., Nov. 2, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, presented an abstract at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions on November 2, 2010 in Vancouver, BC, Canada.  The abstract is titled "Sustained Inhibition of Factor IXa by Subcutaneous RB006 with Active Reversal: First-in-Human Experience with the REG2 System."

The REG2 system is intended for use in venous thrombosis indications.  This initial Phase 1 study was the first successful subcutaneous application of an aptamer in humans.  It demonstrated that a single subcutaneous injection of RB006 (aka pegnivacogin) resulted in dose-dependent inhibition of Factor IXa with effects that persisted longer than one week after injection. The data is promising for future development of REG2.

The abstract is coauthored by Steven L. Zelenkofske, D.O., Christopher P. Rusconi, Ph.D. and Carolyn M. Darmiento, MS, all from Regado Biosciences; and Richard C. Becker, MD, Duke University School of Medicine, Durham, NC and William Wargin, Ph.D., President of PK-PM Associates, LLC.  

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market i
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
10. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Commonwealth Cornerstone Group (CCG) today announced the completion ... Tuesday to help fund the expansion and consolidation of healthcare ... Sharon . PHN is the largest ... . It is the largest employer in Sharon,s ... on staff. Currently, PHN Sharon offers scattered services ...
(Date:12/24/2014)...  The International Trade Commission (ITC) issued its final decision ... In a notice issued on December 23, the ITC ruled ... its humidifier was invalid. BMC President, James ... very excited with the ITC,s decision in this case. This ... since the very beginning on the key patents in the ...
(Date:12/24/2014)... YORK and LONDON , ... global orthopedic industry are expected to grow at an ... in terms of value and volume. Hip, knee and ... developed world while in emerging economies they have a ... rates are challenging the use of composites. Non-metallic orthopedic ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... STAAR Surgical Company (NASDAQ: STAA ), a ... products, today reported financial results for the first quarter ... 8% to $14.8 million over the first quarter of ... and ICL) sales.  The Company achieved its first quarter ...
... 3, 2011 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) ... Total revenues for the quarter ended March ... the first quarter of 2010.  Total revenues included net product ... for the first quarter of 2011 was $21.8 million, or ...
Cached Medicine Technology:STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 2STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 3STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 4STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 5STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 6STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 7STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 8STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 9STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 10STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 11Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 2Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 3Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 4Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 5Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 6Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 7
(Date:12/24/2014)... say they have used human embryonic stem cells to ... While this had already been done using rodent stem ... of cells -- called primordial germ cells -- have ... the team at the University of Cambridge in England. ... of the earliest events during early mammalian development," study ...
(Date:12/24/2014)... 2014 (HealthDay News) -- A lab technician with the ... been exposed to the Ebola virus in an agency ... to a dozen other lab workers are being checked ... The possible exposure occurred Monday when CDC scientists ... the potentially lethal virus to another CDC lab in ...
(Date:12/24/2014)... 2014 Gluten, a protein found predominately ... have an intolerance to gluten, causing side effects that ... headaches, joint pain and fatigue. For this reason, Diet ... that deliver safe and fast weight loss while teaching ... gluten allergy reaction. These gluten free diet plans combine ...
(Date:12/24/2014)... Florida (PRWEB) December 24, 2014 The Healthy ... safer place to raise families. In-Vest USA ... who protect us – our first responders. Today, these two ... enforcement officers by providing them with body armor through In-Vest’s ... the tragic shootings that happened this past week in New ...
(Date:12/24/2014)... Texas (PRWEB) December 24, 2014 ... Industry is a professional and in-depth research report ... report introduces COC basic information, including its definition, ... analysis, news analysis, etc. This report also presents ... etc. Production is separated by regions, technology and ...
Breaking Medicine News(10 mins):Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:The Healthy Home Company and In-Vest USA Team Up to Save the Lives of Law Enforcement 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
... it has launched the authorized generic version of Merck's Proscar ... ,The company has also launched the authorized generic version of ... 40 mg and 80 mg yesterday, a company release said. ... separate agreements with Merck that enabled it to launch the ...
... women-only Fatima Jinnah University in Rawalpindi is embroiled in ... ,Opposition members in the National Assembly protested ... sister of Mohammad Ali Jinnah, the founder of Pakistan. ... Daily Times that a portion of the campus had ...
... the All India Institute of Medical Sciences (AIIMS) is contemplating ... //by "some colleagues and misguided students". ,"The day ... post of vice-chancellor of K.G. Medical University in Lucknow. I ... the prevalent situation (in AIIMS)," said R.C. Deka, a leading ...
... heart transplants are on the decline. This is because the ... doctors at the Papworth Hospital in Cambridge pioneered an operation ... after it was removed from the donor. The first patient ... Burt, 58, a builder from Burnham Market, Norfolk. ...
... given hopes that researchers will be able to re-establish ... humans challenged by deafness//. ,These tiny hairs in the ear ... the brain into sound. Once lost, these hairs could ... , ,Approximately, one out of every twenty-four people, across the ...
... by Canadian researchers show that the male survivors ... are not recognized and understood// many health care ... found that though both male and female childhood ... and fears about their encounters with health care ...
Cached Medicine News:Health News:'Humiliated' Dean Contemplates Leaving AIIMS 2Health News:'Humiliated' Dean Contemplates Leaving AIIMS 3Health News:Latest In the Heart Transplant Field 2Health News:Sexually Abused Males Found Struggling In heir relations with Healthcare Providers 2
... Tissue Sectioning System has maintained the reputation ... Researchers from around the globe have relied ... fresh and fresh fixed tissue sectioning needs ... the Vibratome Automatic Tissue Sectioning Systems, the ...
Replacement bulb for Vibratome light system....
Injector blades come ten to an injector and allow for the easy replacement of Vibratome cutting blades....
Vibratome Specimen Adhesive is a special formulation developed by a major adhesive manufacturer for applications such as tissue mounting. The advantage of this adhesive is that it has a strong holdi...
Medicine Products: